Objective: To determine if the intensity of fluorine-18-fluorodeoxyglucose (FDG) uptake in primary non-small cell lung cancer (NSCLC) could independently predict patient prognosis. Methods: Thirty-eight patients with untreated NSCLC were studied with FDG-PET. Primary tumor FDG uptake was calculated by the standardized uptake value based on lean body mass (SUV-lean). Cumulative survival rate and the SUV-lean were compared. Results: There were no significant differences between the tumor stages and the SUV-lean. Although the survival rates significantly decreased as the stage progressed (p = .0049), there was no significant difference in the survival rate between the group with lower primary tumor FDG uptake (SUV-lean ≤ 8.72) and the group with higher tumor FDG uptake (SUV-lean > 8.72) (p = .2256). However, in the subset of patients without metastasis, survival tended to be longer with a lower tumor SUV-lean. Conclusion: In this population of patients with NSCLC, the tumor FDG uptake does not independently predict the prognosis.
- 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG)
- Emission Computed Tomography
- Non-small Cell Lung Cancer
- Positron Emission Tomography (PET)
- Standardized Uptake Value (SUV)